



Optimized Mealtime Insulin Dosing for Fat and Protein in Type 1 Diabetes: Application of a Model-Based Approach to Derive Insulin Doses for Open-Loop Diabetes Management

Diabetes Care 2016;39:1631–1634 | DOI: 10.2337/dc15-2855

Kirstine J. Bell,^{1,2} Elena Toschi,^{2,3}
Garry M. Steil,^{3,4} and
Howard A. Wolpert^{2,3}

OBJECTIVE

To determine insulin dose adjustments required for coverage of high-fat, high-protein (HFHP) meals in type 1 diabetes (T1D).

RESEARCH DESIGN AND METHODS

Ten adults with T1D received low-fat, low-protein (LFLP) and HFHP meals with identical carbohydrate content, covered with identical insulin doses. On subsequent occasions, subjects repeated the HFHP meal with an adaptive model-predictive insulin bolus until target postprandial glycemic control was achieved.

RESULTS

With the same insulin dose, the HFHP increased the glucose incremental area under the curve over twofold ($13,320 \pm 2,960$ vs. $27,092 \pm 1,709$ mg/dL · min; $P = 0.0013$). To achieve target glucose control following the HFHP, 65% more insulin was required (range 17%–124%) with a 30%/70% split over 2.4 h.

CONCLUSIONS

This study demonstrates that insulin dose calculations need to consider meal composition in addition to carbohydrate content and provides the foundation for new insulin-dosing algorithms to cover meals of varying macronutrient composition.

Studies have demonstrated that dietary fat and protein cause postprandial hyperglycemia in patients with type 1 diabetes (T1D) (1), but definitive experimental data to guide clinical practice recommendations on how to adjust prandial insulin doses for higher fat and higher protein meals are lacking.

The objective of the current study was to 1) determine the incremental differences in postprandial glycemia following a high-fat, high-protein (HFHP) meal compared with a low-fat, low-protein (LFLP) meal with identical carbohydrate content and 2) determine how insulin doses should be adjusted to cover the HFHP meal.

RESEARCH DESIGN AND METHODS

Subjects

Ten adults with T1D using insulin pump and continuous glucose monitoring, aged 18–75 years, with T1D for >3 years, using an insulin pump for >6 months, and with

¹Charles Perkins Centre and the School of Molecular Bioscience, The University of Sydney, Sydney, New South Wales, Australia

²Joslin Diabetes Center, Boston, MA

³Harvard Medical School, Boston, MA

⁴Boston Children's Hospital, Boston, MA

Corresponding author: Howard A. Wolpert, howard.wolpert@joslin.harvard.edu.

Received 31 December 2015 and accepted 24 May 2016.

Clinical trial reg. no. NCT02248454, clinicaltrials.gov.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-2855/-/DC1>.

© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://diabetesjournals.org/site/license>.

an $HbA_{1c} < 8.5\%$ (69 mmol/mol) were studied. The study was approved by the Joslin Institutional Review Board.

Study Protocol

Prior to the study all pump settings were optimized. One day prior to admission subjects inserted a new continuous glucose monitoring sensor, insulin infusion catheter, and reservoir filled with Lispro insulin (Lilly, Indianapolis, IN). After a 10-h fast, subjects were admitted to the Joslin Clinical Research Center. On admission, an intravenous catheter for blood sampling was inserted and the pump changed to an Animas OneTouch Ping (West Chester, PA). If the glucose concentration was outside the target range (80–130 mg/dL), a correction insulin dose or glucose tablets was administered as necessary and the test was delayed for 2.5 h.

On the first two admissions subjects consumed LFLP and HFHP meals in random order, with an identical insulin bolus calculated using their carbohydrate-to-insulin ratio (CIR) (delivered as a 50%/50% combination bolus over 2 h). On subsequent visits, subjects repeated the HFHP meal with an insulin dose estimated using a model predictive bolus (MPB) algorithm (details reported in the Supplementary Data). Visits were repeated up to four times until the following glucose criteria were achieved:

1. ≤ 10 mg/dL decrease from baseline (BL) during the first 2 h
2. Peak postprandial glucose \leq BL plus 80 mg/dL
3. 2-h postprandial glucose \leq BL plus 40 mg/dL
4. 6-h postprandial glucose within 20 mg/dL of BL
5. No hypoglycemia requiring treatment

Glucose concentrations were assessed using an YSI 2300 glucose analyzer (YSI, Yellow Springs, OH) from venous blood samples taken -30 , -20 , and 0 min prior to the meal and every 30 min thereafter for 6 h.

Diet

The meals consisted of a pizza base with marinara sauce (LFLP) or the same pizza base and sauce with added cheese (HFHP). Meals were prepared the morning of the session. The two meals were matched for carbohydrate (50 g), but varied in calories, fat, and protein: LFLP

had 273 calories, 4 g of fat, and 9 g of protein and HFHP had 764 calories, 44 g of fat, and 36 g of protein. The pizza base had a glycemic index (GI) of 52 (J. Brand-Miller and K.J.B., unpublished data). Additional nutrition information is reported in Supplementary Table 1.

Adaptive MPB Algorithm

The MPB algorithm was applied in two steps. First, a metabolic model comprising an insulin pharmacokinetic/pharmacodynamic submodel (2), the Bergman minimal model (3,4), and a meal absorption model (5) was identified using a nonlinear generalized reduced gradient algorithm available in Microsoft Excel (Office 2013). Second, an optimal insulin DOSE (U), SPLIT (% given as bolus), and DURATION were obtained by minimizing the model-predicted glucose area below target from 0 to 120 min and area above target from 120 to 360 min following the meal. DOSE was constrained to be ≤ 1.75 times the previous maximum DOSE; if the constrained DOSE did not achieve the desired glucose criteria, the procedure was repeated. Further details on the model are provided in studies characterizing the effect of dietary fat on insulin requirements (6) and intraday changes in metabolism (7,8).

Statistical Analysis

Outcome data are reported as mean \pm SE. Changes in insulin DOSE and glucose incremental area under the curve (iAUC) were assessed by repeated-measures ANOVA with correction for multiple

comparisons (Dunnnett procedure with the LFLP meal as control). Patient demographics are reported as mean \pm SD. Statistical testing was done using GraphPad Prism, version 6.04.

RESULTS

Patient Characteristics

Ten patients (nine male, one female) were studied. Mean \pm SD age was 60.4 ± 11.3 years, BMI was 25.8 ± 3.5 kg/m², HbA_{1c} was $7.1 \pm 0.8\%$ (54 ± 7 mmol/mol), and total daily insulin dose was 35.5 ± 14.8 U/day (range 17–65 U/day).

LFLP Meal Versus HFHP Meal

Fasting blood glucose concentrations on the two study days were similar (127 ± 8 mg/dL vs. 129 ± 5 mg/dL, $P = 0.702$). Despite using the same insulin dose, the glucose iAUC in the HFHP meal was more than double that of LFLP meal ($27,092 \pm 1,709$ vs. $13,320 \pm 2,960$ mg/dL \cdot min; $P = 0.0013$), with significant differences observed from 180 min onwards and >100 mg/dL differences in glucose concentrations at 6 h (Fig. 1).

Optimized Insulin Dose

In 7 of the 10 subjects, the model-optimized meal profile achieved our stopping criteria in one attempt. In 2 subjects the initial MPB was too high and in 1 subject the initial dose was too low, necessitating additional 2–3 visits. MPB decreased the glucose iAUC ($27,092 \pm 1,709$ mg/dL \cdot min to $11,712 \pm 3,172$ mg/dL \cdot min; $P = 0.0013$) and the incremental change in blood glucose concentration (73 ± 4 mg/dL to 24 ± 11 mg/dL; $P = 0.001$). Additional




Figure 1—Postprandial plasma glucose response following LFLP and HFHP meals with identical carbohydrate content and insulin dose and an HFHP meal with optimal MPB (HFHP_{MPB}).

- subjects: a minimal model index. *J Clin Endocrinol Metab* 2000;85:4396–4402
5. Wilinska ME, Chassin LJ, Acerini CL, Allen JM, Dunger DB, Hovorka R. Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes. *J Diabetes Sci Technol* 2010;4:132–144
6. Laxminarayan S, Reifman J, Edwards SS, Wolpert H, Steil GM. Bolus estimation—rethinking the effect of meal fat content. *Diabetes Technol Ther* 2015;17:860–866
7. Kanderian SS, Weinzimer S, Voskanyan G, Steil GM. Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes. *J Diabetes Sci Technol* 2009;3:1047–1057
8. Kanderian SS, Weinzimer SA, Steil GM. The identifiable virtual patient model: comparison of simulation and clinical closed-loop study results. *J Diabetes Sci Technol* 2012;6:371–379
9. De Palma A, Giani E, Iafusco D, et al. Lowering postprandial glycemia in children with type 1 diabetes after Italian pizza “margherita” (TyBoDi2 Study). *Diabetes Technol Ther* 2011;13:483–487
10. Chase HP, Saib SZ, MacKenzie T, Hansen MM, Garg SK. Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. *Diabet Med* 2002;19:317–321
11. Jones SM, Quarry JL, Caldwell-McMillan M, Mauger DT, Gabbay RA. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. *Diabetes Technol Ther* 2005;7:233–240
12. Wolpert HA, Atakov-Castillo A, Smith SA, Steil GM. Dietary fat acutely increases glucose concentrations and insulin requirements in patients with type 1 diabetes: implications for carbohydrate-based bolus dose calculation and intensive diabetes management. *Diabetes Care* 2013;36:810–816
13. Thabit H, Tauschmann M, Allen JM, et al.; APCam Consortium; AP@home Consortium. Home use of an artificial beta cell in type 1 diabetes. *N Engl J Med* 2015;373:2129–2140
14. Pańkowska E, Szybowska A, Lipka M, Szpotkańska M, Błazik M, Groele L. Application of novel dual wave meal bolus and its impact on glycated hemoglobin A1c level in children with type 1 diabetes. *Pediatr Diabetes* 2009;10:298–303
15. Pańkowska E, Błazik M, Groele L. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. *Diabetes Technol Ther* 2012;14:16–22
16. Kordonouri O, Hartmann R, Remus K, Bläsing S, Sadeghian E, Danne T. Benefit of supplementary fat plus protein counting as compared with conventional carbohydrate counting for insulin bolus calculation in children with pump therapy. *Pediatr Diabetes* 2012;13:540–544
17. Bao J, Gilbertson HR, Gray R, et al. Improving the estimation of mealtime insulin dose in adults with type 1 diabetes: the Normal Insulin Demand for Dose Adjustment (NIDDA) study. *Diabetes Care* 2011;34:2146–2151
18. Bell KJ, Gray R, Munns D, et al. Estimating insulin demand for protein-containing foods using the Food Insulin Index. *Eur J Clin Nutr* 2014;68:1055–1059
19. Smart CEM, Evans M, O’Connell SM, et al. Both dietary protein and fat increase postprandial glucose excursions in children with type 1 diabetes, and the effect is additive. *Diabetes Care* 2013;36:3897–3902